KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:待检查

Maintenance Therapy in Acute Myeloid Leukemia: Current Perspectives and Future Directions.

Pilar Velarde, Asmaa Aloufi, David Sanford

Curr Oncol 33(6) 369

PMID42346269
PMCIDPMC13298856
DOI10.3390/curroncol33060369
发表日期2026-06-25
AI 判定该论文不进入自动 KM 提取:This is a review article summarizing existing evidence, not a report of original results from a human Phase III randomized controlled clinical trial.
摘要

摘要

The management of acute myeloid leukemia (AML) remains characterized by high relapse rates despite advances in induction and consolidation therapy. Relapse prevention represents a major unmet need, particularly in patients ineligible for allogeneic hematopoietic stem cell transplantation (allo-HSCT) or at high risk of post-transplant recurrence. This review examines current evidence supporting maintenance strategies following intensive chemotherapy or allo-HSCT, with emphasis on measurable residual disease (MRD)-guided approaches and targeted therapies. We summarize data from randomized and phase II/III trials evaluating hypomethylating agents, FLT3 inhibitors, IDH inhibitors, and immunotherapeutic strategies in post-remission settings. Oral azacitidine (CC-486) demonstrated overall survival benefit in older patients in first complete remission who were not transplant candidates, establishing a standard of care in this population. In FLT3-mutated AML, post-transplant maintenance with sorafenib and gilteritinib reduces relapse risk, with emerging evidence supporting MRD as a predictive biomarker for benefit. Other targeted agents and immunotherapies have shown promising early-phase results, although confirmatory data are limited. Ongoing phase III studies will clarify optimal patient selection, treatment duration, and integration with transplantation, aiming to transform post-remission management from passive surveillance to precision-based relapse prevention.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。